Author

A. K. Mallick

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:mouse· 3 Research Focus:differential expression· 1

Frequent Co-Authors

A. Adhikari· 3 shared A. K. Das· 3 shared M. Das· 3 shared S. Darbar· 3 shared S. K. Pal· 3 shared S. Mondal· 3 shared D. Pal· 2 shared P. Biswas· 2 shared

Activity by Year

2020-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersPharmacology & Toxicology

A. Adhikari

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Redox Buffering Capacity of Nanomaterials as an Index of ROS-based Therapeutics and Toxicity: A Preclinical Animal Study

A. Adhikari, S. Mondal, M. Das, R. Ghosh, P. Biswas, S. Darbar, A. K. Das, S. Bhattacharya, D. Pal, A. K. Mallick, S. K. Pal

This study evaluates the redox buffering capacity of nanomaterials to assess their therapeutic potential and toxicity in a preclinical animal model.

bioRxiv · Mar 14, 2021Pharmacology & Toxicology

A Nanoceutical Agent for Chemoprevention of Bilirubin Encephalopathy

A. Adhikari, V. K. Bhutani, S. Mondal, M. Das, S. Darbar, R. Ghosh, N. Polley, A. K. Das, S. S. Bhattacharya, A. K. Mallick, S. K. Pal

This paper reports on the development and testing of citrate-functionalized Mn3O4 nanoparticles for the prevention of bilirubin encephalopathy in a mouse model of neonatal hyperbilirubinemia.

bioRxiv · Dec 31, 2020 · PreprintPharmacology & Toxicology

Incorporation of a Biocompatible Nanozyme in Cellular Antioxidant Enzyme Cascade Reverses Huntington's Like Disorder in Preclinical Model

A. Adhikari, S. Mondal, M. Das, P. Biswas, U. Pal, S. Darbar, S. S. Bhattacharya, D. Pal, T. Saha-Dasgupta, A. K. Das, A. K. Mallick, S. K. Pal

This paper demonstrates that a biocompatible nanozyme can reverse Huntington's-like disorder in a preclinical model by mimicking glutathione peroxidase and integrating into the cellular antioxidant cascade.

bioRxiv · Sep 23, 2020Pharmacology & Toxicology